NCT03544736View on ClinicalTrials.gov

Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2040

Conditions

Esophageal Cancer

Interventions

DRUG

Nivolumab

Experimental: Nivolumab

RADIATION

Radiotherapy

Radiotherapy

DRUG

Chemotherapy

Chemotherapy

PROCEDURE

Surgery

Surgery

Trial Locations (1)

0424

Oslo University Hospital, Oslo

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Oslo University Hospital

OTHER

NCT03544736 - Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | Biotech Hunter | Biotech Hunter